Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts

Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocols children and adults’ overall survival (OS) rates reach 85–90% and 40–50%, respec...

Full description

Bibliographic Details
Main Authors: Sonia Minuzzo, Valentina Agnusdei, Marica Pinazza, Adriana A. Amaro, Valeria Sacchetto, Ulrich Pfeffer, Roberta Bertorelle, Orietta Spinelli, Valentina Serafin, Stefano Indraccolo
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Experimental Hematology & Oncology
Subjects:
T-ALL
Relapse
anti-NOTCH1
Antimetabolites
Online Access:https://doi.org/10.1186/s40164-023-00439-6

Internet

https://doi.org/10.1186/s40164-023-00439-6

Similar Items